Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

June 15, 2020

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
June 10, 2020

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
June 9, 2020

Immunic, Inc. Announces Proposed Public Offering of Common Stock
June 9, 2020

Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
May 29, 2020

Immunic, Inc. to Participate in Investor and Industry Conferences in June
May 19, 2020

Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020

- Presentation Will Include Preclinical Data of IMU-838 Against SARS-CoV-2 as Well as First Pharmacokinetic Data From the Ongoing Phase 1 Clinical Trial of IMU-935 -
May 13, 2020

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients
May 8, 2020

Immunic, Inc. Reports First Quarter 2020 Financial Results and Highlights Recent Activity
April 23, 2020

Immunic, Inc. Announces Pricing of $15 Million Financing
April 21, 2020

Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

- In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit Viral Replication of SARS-CoV-2 -

Show per page